Baxter (NYSE: BAX), a leading provider of healthcare products, has announced the appointment of Wu Xin as its China General Manager, effective from October 7, as reported by MedTalent. This strategic move comes amidst the company’s spin-off of its global kidney care business and acute treatment business, which will operate under the brand Vantive. Wu will collaborate closely with Xu Runhong, the General Manager of Kidney Care China, to ensure a smooth transition and secure the spin-off operations.
Spin-Off and Leadership Transition
Baxter’s decision to spin off its kidney care and acute treatment business sectors into an independent new company was announced in January of this year. The two units contributed significantly to the company’s 2022 revenues, generating USD 4.5 billion, which accounted for a quarter of Baxter’s total USD 15.113 billion revenue, as per its financial report. The new entity was named Vantive in July, marking a significant step in the company’s restructuring.
Responsibilities and Future Outlook
Following the spin-off, Xu Runhong, the former president of Baxter China, will manage the operations of Vantive in China. Wu Xin will be tasked with overseeing the remaining business operations in the country. This leadership transition is expected to facilitate the successful separation of the businesses and ensure continuity in Baxter’s operations and growth in the Chinese market.-Fineline Info & Tech
